ALN-APP was designed to treat early-onset Alzheimer’s disease (EOAD) by attaching siRNAs to a lipophilic C16 fatty acid chain, which significantly enhanced the distribution of the siRNA in the brains of rats and monkeys after intrathecal injection. This evidence concerns the gene ARLN and Alzheimer disease.